OncLive Peer Exchange®

Expert perspectives on the evolving treatment landscape of HR+ breast cancer and how novel therapies have been incorporated in practice.

Expert perspectives on molecular testing and best practices for identifying patients who may be eligible for treatment with newly approved targeted therapies.

A panel made up of expert hematologists Ryan Cassaday, MD, Armin Ghobadi, MD, Elias Jabbour, MD, and Gary J. Schiller, MD discusses current standards-of-care in Acute Lymphoblastic Leukemia as well as key data presented at the American Society of Hematology’s 2022 Annual Meeting.

Expert oncologists review recent updates in the treatment of acute myeloid leukemia (AML) that were presented at key conferences in 2022.

Five experts in the field of MDS highlight recent data updates, including those presented at the 2022 American Society of Hematology (ASH) Annual Meeting.

A panel of experts summarizes the current HR+ breast cancer treatment landscape and discusses recent data updates in the field, including those presented at the 2022 San Antonio Breast Cancer Symposium (SABCS).

A distinguished panel of experts in hematologic malignancies have an engaging discussion on the current and potential future treatment approaches for MCL.

Expert hematologist-oncologists review key updates in the treatment of CLL presented at recent conferences and consider their impact on clinical practice.

Panel of oncologists define graft vs host disease (GvHD), review the current landscape and discuss the future of GvHD treatment.

Shared insight from a panel of key opinion leaders on the evolving treatment landscape of myeloproliferative neoplasms and improvements in care.

Sponsored in part by Amgen Oncology and Sanofi. Content independently created by OncLive.

Joseph Mikhael, MD, and panelists present a case of a 63-year-old woman with early relapse multiple myeloma and discuss the impact of updated trial data on treatment decision-making for patients.

A panel of key opinion leaders gather for a discussion on recent data updates in the treatment of multiple myeloma that were recently presented at ASH 2022, and how they impact clinical practice and treatment recommendations.

A panel of oncologists review recent data from the ZUMA-7 trial and provide a comprehensive review of thetreatment options for patients with R/R DLBCL.

A panel of esteemed nurse practitioners discusses how endometrial cancer is diagnosed, the process of treatment decision-making, and the management of adverse effects in patients undergoing treatment.

A panel of esteemed physicians review recent key data updates in ovarian cancer from ESMO 2022, including late-breaking news.

A multidisciplinary panel discusses recent updates and advances in molecular testing and treatment for stage I-IIIA non-small cell lung cancer (NSCLC).

Centering discussion on clinical trial data and real-world patient profiles, expert oncologists review the treatment paradigm for hepatocellular carcinoma and consider how they would sequence therapy.

In the context of recent and ongoing clinical trials, expert oncologists provide comprehensive insight to the evolving treatment landscape of both clear cell and non–clear cell advanced RCC.

A global panel of experts discusses several recent data updates on the role of immunotherapy in non-small cell lung cancer (NSCLC) and their impact on clinical practice.

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

Expert panelists share insight on factors that lead to disparities in the management of multiple myeloma among racial and ethnic minority groups and strategies to address these disparities.

Expert panelists review the current treatment landscape of biliary tract cancers and consider how the field may evolve in light of novel therapeutic strategies in the pipeline.

A panel of experts discusses the testing and targeting of HER2 in non-small cell lung cancer (NSCLC) and the impact of recent clinical trial data on treatment selection.

A panel of experts discusses molecular testing and the use of targeted agents in lung and breast cancers, including best practices for ordering testing and how to factor results into treatment decisions.

A panel of experts in oncology review the use of antibody drug conjugates (ADCs) in breast and gastric cancers, defining optimal management of ADC-related adverse events.

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®

A distinguished panel of experts in hematologic malignancies builds a lively discussion on recent clinical trials and potential advancements in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.

Expert panelists elucidate the evolving field of graft versus host disease management, highlighting novel therapies and treatment approaches.

Expert panelists review new data on the management of immune thrombocytopenia and consider how these data may impact clinical practice.

A panel of experts discusses newly presented data from ASCO 2022 and how it affects potential treatment approaches for relapsed/refractory DLBCL.

Expert hematologist-oncologists Ajai Chari, MD; Krina Patel MD; Christina Gasparetto, MD; Rafael Fonseca, MD; and Omar Nadeem, MD, review data from ASCO and share updates on the management of multiple myeloma.